Ganglioside GM2

Ganglioside GM2 is a lipid of Sphingolipids (SP) class. Ganglioside gm2 is associated with abnormalities such as Sensory neuropathy, Neuropathy, Autoimmune Diseases, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating and Neuromuscular Diseases. The involved functions are known as Pressure- physical agent, Cytolysis, Inflammation, Complement-Dependent Cytotoxicity and conjugation. Ganglioside gm2 often locates in Membrane, Entire nervous system, Cell surface, Biopsy sample and Lipid Bilayers. The associated genes with Ganglioside GM2 are anti-IgM, Polypeptides, Transgenes, Alleles and Homologous Gene. The related lipids are Ganglioside GA2, QS 21, sulfate-3-glucuronyl paragloboside, Lipopolysaccharides and IV(4)-galactosyl-N-acetylganglioside GD1a. The related experimental models are Disease model.

Cross Reference

Introduction

To understand associated biological information of Ganglioside GM2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Ganglioside GM2?

Ganglioside GM2 is suspected in Tay-Sachs Disease, Gangliosidoses GM2, Sandhoff Disease, Neuropathy, Cytomegalovirus Infections, Niemann-Pick Diseases and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

No disease MeSH terms mapped to the current reference collection.

PubChem Associated disorders and diseases

What pathways are associated with Ganglioside GM2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Ganglioside GM2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Ganglioside GM2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Ganglioside GM2?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Ganglioside GM2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Ganglioside GM2?

Disease model

Disease model are used in the study 'Development of GlcNAc-inspired iminocyclitiols as potent and selective N-acetyl-beta-hexosaminidase inhibitors.' (Ho CW et al., 2010) and Disease model are used in the study 'Therapeutic evaluation of GM2 gangliosidoses by ELISA using anti-GM2 ganglioside antibodies.' (Tsuji D et al., 2007).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Ganglioside GM2

Download all related citations
Per page 10 20 50 100 | Total 558
Authors Title Published Journal PubMed Link
Sato M et al. Accumulation of cholesterol and GM2 ganglioside in cells cultured in the presence of progesterone: an implication for the basic defect in Niemann-Pick disease type C. 1998 Brain Dev. pmid:9533562
Watanabe Y et al. Increased levels of GM2 ganglioside in fibroblasts from a patient with juvenile Niemann-Pick disease type C. 1998 Brain Dev. pmid:9545179
Bitzan MM et al. Inhibition of Helicobacter pylori and Helicobacter mustelae binding to lipid receptors by bovine colostrum. 1998 J. Infect. Dis. pmid:9534968
Xie B et al. Biochemical characterization of the Cys138Arg substitution associated with the AB variant form of GM2 gangliosidosis: evidence that Cys138 is required for the recognition of the GM2 activator/GM2 ganglioside complex by beta-hexosaminidase A. 1998 Biochemistry pmid:9454570
Yuziuk JA et al. Specificity of mouse GM2 activator protein and beta-N-acetylhexosaminidases A and B. Similarities and differences with their human counterparts in the catabolism of GM2. 1998 J. Biol. Chem. pmid:9417048
Dotta F et al. The GM2-1 ganglioside islet autoantigen in insulin-dependent diabetes mellitus is expressed in secretory granules and is not beta-cell specific. 1998 Endocrinology pmid:9421429
Cavanna B et al. Anti-GM2 IgM antibodies: clinical correlates and reactivity with a human neuroblastoma cell line. 1999 J. Neuroimmunol. pmid:10376949
Kolter T et al. Recent advances in the biochemistry of glycosphingolipid metabolism. 1999 Biochem. Soc. Trans. pmid:10917612
Mahuran DJ Biochemical consequences of mutations causing the GM2 gangliosidoses. 1999 Biochim. Biophys. Acta pmid:10571007
Nakamura K et al. Apoptosis induction of human lung cancer cell line in multicellular heterospheroids with humanized antiganglioside GM2 monoclonal antibody. 1999 Cancer Res. pmid:10537316
Zuberbier T et al. Alterations in ganglioside expression during the differentiation of human mast cells. 1999 Exp. Dermatol. pmid:10536964
Okada N et al. Human IgM monoclonal antibody to ganglioside GM2 and complement suppress virus propagation in ex vivo cultures of lymphocytes from HIV-1 infected patients. 1999 Microbiol. Immunol. pmid:10529115
Okada N and Okada H Human IgM antibody therapy for HIV-1 infection. 1999 Microbiol. Immunol. pmid:10524789
Sorice M et al. Glycosphingolipid domains on cell plasma membrane. 1999 Biosci. Rep. pmid:10513897
Zervas M and Walkley SU Ferret pyramidal cell dendritogenesis: changes in morphology and ganglioside expression during cortical development. 1999 J. Comp. Neurol. pmid:10502250
Gori AH et al. Mediation of attachment of Burkholderia pseudomallei to human pharyngeal epithelial cells by the asialoganglioside GM1-GM2 receptor complex. 1999 Am. J. Trop. Med. Hyg. pmid:10497993
Macias A et al. Novel cross-reactive anti-idiotype antibodies with properties close to the human intravenous immunoglobulin (IVIg). 1999 Hybridoma pmid:10475241
Ecsedy JA et al. Expression of mouse sialic acid on gangliosides of a human glioma grown as a xenograft in SCID mice. 1999 J. Neurochem. pmid:10386978
Raghavan S et al. G(M2)-ganglioside metabolism in situ in mucolipidosis IV fibroblasts. 1999 Neurochem. Res. pmid:10227679
Mizutani K et al. Enhancement of TNF-alpha production by ganglioside GM2 in human mononuclear cell culture. 1999 Neuroreport pmid:10208534
Li YT et al. Structural basis for the resistance of Tay-Sachs ganglioside GM2 to enzymatic degradation. 1999 J. Biol. Chem. pmid:10187778
Khalili-Shirazi A et al. Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection. 1999 J. Neurol. Neurosurg. Psychiatry pmid:10084538
Mundel TM et al. Ganglioside GM2-activator protein and vesicular transport in collecting duct intercalated cells. 1999 J. Am. Soc. Nephrol. pmid:10073593
Takahashi T et al. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. 1999 J. Invest. Dermatol. pmid:9989797
Usuki S et al. GM2 promotes ciliary neurotrophic factor-dependent rescue of immortalized motor neuron-like cell (NSC-34). 1999 Neurochem. Res. pmid:9972876
Sakuraba H et al. GM2 gangliosidosis AB variant: clinical and biochemical studies of a Japanese patient. 1999 Neurology pmid:9932959
Wu X et al. Complement-mediated anti-HIV-1 effect induced by human IgM monoclonal antibody against ganglioside GM2. 1999 J. Immunol. pmid:9886430
Fukumoto H et al. Effect of a chimeric anti-ganglioside GM2 antibody on ganglioside GM2-expressing human solid tumors in vivo. 1999 Int. J. Cancer pmid:10417777
Slevin M et al. Physiological concentrations of gangliosides GM1, GM2 and GM3 differentially modify basic-fibroblast-growth-factor-induced mitogenesis and the associated signalling pathway in endothelial cells. 1999 Int. J. Cancer pmid:10399959
Hanibuchi M et al. Immunological circumvention of multiple organ metastases of multidrug resistant human small cell lung cancer cells by mouse-human chimeric anti-ganglioside GM2 antibody KM966. 2000 Clin. Exp. Metastasis pmid:11467766
Hedberg KM et al. Monoclonal anti-GD3 antibodies selectively inhibit the proliferation of human malignant glioma cells in vitro. 2000 Glycoconj. J. pmid:11425192
Nakamura K et al. Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody. 2000 Mol. Immunol. pmid:11399321
Chapman PB et al. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin. 2000 Clin. Cancer Res. pmid:11156217
Chiavegatto S et al. A functional role for complex gangliosides: motor deficits in GM2/GD2 synthase knockout mice. 2000 Exp. Neurol. pmid:11085888
Portoukalian J Immunogenicity of glycolipids. 2000 Clin Rev Allergy Immunol pmid:11064828
Wu X et al. The IgM antibody level against ganglioside GM2 correlates to the disease status of HIV-1-infected patients. 2000 Microbiol. Immunol. pmid:10888361
Tsurifune T et al. Alteration of tumor phenotypes of B16 melanoma after genetic remodeling of the ganglioside profile. 2000 Int. J. Oncol. pmid:10853034
Chapman PB et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. 2000 Clin. Cancer Res. pmid:10741710
Ang CW et al. Campylobacter jejuni lipopolysaccharides from Guillain-Barré syndrome patients induce IgG anti-GM1 antibodies in rabbits. 2000 J. Neuroimmunol. pmid:10713352
Brezicka T et al. Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues. 2000 Lung Cancer pmid:10704706
Pospisil M et al. Cancer immunomodulation by carbohydrate ligands for the lymphocyte receptor NKR-P1. 2000 Int. J. Oncol. pmid:10639569
Bierfreund U et al. Sphingolipid hydrolases and activator proteins. 2000 Meth. Enzymol. pmid:10563332
Ang CW et al. Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome. 2000 Neurology pmid:10751257
Taniguchi M et al. Sites and temporal changes of gangliosides GM1/GM2 storage in the Niemann-Pick disease type C mouse brain. 2001 Brain Dev. pmid:11578853
Teixeira CA et al. Retrovirus-mediated transfer and expression of beta-hexosaminidase alpha-chain cDNA in human fibroblasts from G(M2)-gangliosidosis B1 variant. 2001 Hum. Gene Ther. pmid:11560770
Beccari T et al. Promoter characterization and expression of the gene coding for the human GM2 activator protein. 2001 Biosci. Rep. pmid:11508694
Saito M and Sugiyama K Gangliosides in rat kidney: composition, distribution, and developmental changes. 2001 Arch. Biochem. Biophys. pmid:11360994
Kirkwood JM et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. 2001 J. Clin. Oncol. pmid:11331315
Werth N et al. Degradation of membrane-bound ganglioside GM2 by beta -hexosaminidase A. Stimulation by GM2 activator protein and lysosomal lipids. 2001 J. Biol. Chem. pmid:11278374
Parajuli P et al. Humanized anti-ganglioside GM2 antibody is effective to induce antibody-dependent cell-mediated cytotoxicity in mononuclear cells from lung cancer patients. 2001 Cancer Lett. pmid:11275367
Kirkwood JM et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. 2001 J. Clin. Oncol. pmid:11230488
Kaida K et al. Guillain-Barré syndrome with IgM antibody to the ganglioside GalNAc-GD1a. 2001 J. Neuroimmunol. pmid:11164910
Mattson MP New blood cells help an overburdened brain. 2001 Trends Neurosci. pmid:11163874
Sueyoshi N et al. Apoptosis of Neuro2a cells induced by lysosphingolipids with naturally occurring stereochemical configurations. 2001 J. Lipid Res. pmid:11483620
Ortiz N et al. IgM monoclonal antibody against terminal moiety of GM2, GalNAc-GD1a and GalNAc-GM1b from a pure motor chronic demyelinating polyneuropathy patient: effects on neurotransmitter release. 2001 J. Neuroimmunol. pmid:11525808
Cavanna B et al. Anti-GM(2) IgM antibody-induced complement-mediated cytotoxicity in patients with dysimmune neuropathies. 2001 J. Neuroimmunol. pmid:11240036
Gouni-Berthold I et al. Gangliosides GM1 and GM2 induce vascular smooth muscle cell proliferation via extracellular signal-regulated kinase 1/2 pathway. 2001 Hypertension pmid:11711493
Li SC et al. Degradation of G(M1) and G(M2) by mammalian sialidases. 2001 Biochem. J. pmid:11696012
Yoshida S et al. Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. 2001 Cancer Res. pmid:11358851
Ang CW et al. Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits. 2001 Infect. Immun. pmid:11254608
Zervas M et al. Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. 2001 J. Neuropathol. Exp. Neurol. pmid:11202175
Wölfl M et al. Gangliosides inhibit the development from monocytes to dendritic cells. 2002 Clin. Exp. Immunol. pmid:12452834
Martino S et al. Restoration of the GM2 ganglioside metabolism in bone marrow-derived stromal cells from Tay-Sachs disease animal model. 2002 Neurochem. Res. pmid:12374215
Ravasi D et al. Study of interaction of GM2 activator protein with GM2 using circular dichroism and fluorescence spectroscopy. 2002 Neurochem. Res. pmid:12374214
Jeyakumar M et al. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. 2002 Neuropathol. Appl. Neurobiol. pmid:12366816
Jeyakumar M et al. An inducible mouse model of late onset Tay-Sachs disease. 2002 Neurobiol. Dis. pmid:12270683
Niazi KR et al. The CD1b structure: antigen presentation adapts to a high-fat diet. 2002 Nat. Immunol. pmid:12145652
Gadola SD et al. Structure of human CD1b with bound ligands at 2.3 A, a maze for alkyl chains. 2002 Nat. Immunol. pmid:12118248
Lopate G et al. Severe sensory ataxia and demyelinating polyneuropathy with IgM anti-GM2 and GalNAc-GD1A antibodies. 2002 Muscle Nerve pmid:12115971
Myerowitz R et al. Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. 2002 Hum. Mol. Genet. pmid:12019216
Alaedini A et al. Detection of anti-ganglioside antibodies in Guillain-Barré syndrome and its variants by the agglutination assay. 2002 J. Neurol. Sci. pmid:11959155
Martino S et al. Absence of metabolic cross-correction in Tay-Sachs cells: implications for gene therapy. 2002 J. Biol. Chem. pmid:11923278
Sango K et al. Lysosomal storage results in impaired survival but normal neurite outgrowth in dorsal root ganglion neurones from a mouse model of Sandhoff disease. 2002 Neuropathol. Appl. Neurobiol. pmid:11849560
Mehta RR et al. In vitro transformation of human congenital naevus to malignant melanoma. 2002 Melanoma Res. pmid:11828255
Guerry P et al. Phase variation of Campylobacter jejuni 81-176 lipooligosaccharide affects ganglioside mimicry and invasiveness in vitro. 2002 Infect. Immun. pmid:11796612
Miljan EA et al. Interaction of the extracellular domain of the epidermal growth factor receptor with gangliosides. 2002 J. Biol. Chem. pmid:11796728
Trindade VM et al. Ganglioside alterations in the central nervous system of rats chronically injected with methylmalonic and propionic acids. 2002 Metab Brain Dis pmid:12083341
Wendeler M et al. Recombinant ganglioside GM2 synthase--expression in insect cells and enzyme assay. 2003 Meth. Enzymol. pmid:14579597
Li YT et al. Structural basis for the enzymatic resistance of the GM2 ganglioside. 2003 Meth. Enzymol. pmid:14579580
Mauri L et al. Procedure for separation of GM2 ganglioside species with different ceramide structures by a flash reversed-phase silica gel liquid chromatography. 2003 J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. pmid:14552811
Brown ER and Ibrahim JG A Bayesian semiparametric joint hierarchical model for longitudinal and survival data. 2003 Biometrics pmid:12926706
Li YT et al. Presence of an unusual GM2 derivative, taurine-conjugated GM2, in Tay-Sachs brain. 2003 J. Biol. Chem. pmid:12829702
Antoine T et al. Large-scale in vivo synthesis of the carbohydrate moieties of gangliosides GM1 and GM2 by metabolically engineered Escherichia coli. 2003 Chembiochem pmid:12740812
Mizutani K et al. Amyotrophic lateral sclerosis with IgM antibody against gangliosides GM2 and GD2. 2003 Intern. Med. pmid:12705795
Odaka M and Yuki N Antibodies to GM2 ganglioside in neurological disorders. 2003 Intern. Med. pmid:12705785
Yamaguchi A et al. Plasmid-based gene transfer ameliorates visceral storage in a mouse model of Sandhoff disease. 2003 J. Mol. Med. pmid:12682727
Rapoport E et al. Ganglioside binding pattern of CD33-related siglecs. 2003 Bioorg. Med. Chem. Lett. pmid:12639556
Shimada Y et al. Effect of GM2 activator protein on the enzymatic hydrolysis of phospholipids and sphingomyelin. 2003 J. Lipid Res. pmid:12576516
Chen HH et al. Suppression of lung metastasis of mouse Lewis lung cancer P29 with transfection of the ganglioside GM2/GD2 synthase gene. 2003 Int. J. Cancer pmid:12455030
Sharma R et al. A single site in human beta-hexosaminidase A binds both 6-sulfate-groups on hexosamines and the sialic acid moiety of GM2 ganglioside. 2003 Biochim. Biophys. Acta pmid:12527415
Irie S et al. Detection of serum anti-ganglioside antibodies by latex agglutination assay in Guillain-Barré syndrome: comparison with ELISA. 2003 Intern. Med. pmid:12857046
Tada M et al. [Steroid-pulse therapy in Guillain-Barré syndrome associated with cytomegalovirus infection: a case report]. 2003 No To Shinkei pmid:12910997
Pelled D et al. Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin. 2003 J. Biol. Chem. pmid:12756243
Yamato O et al. GM2-gangliosidosis variant 0 (Sandhoff-like disease) in a family of Japanese domestic cats. 2004 Vet. Rec. pmid:15623087
Cressant A et al. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. 2004 J. Neurosci. pmid:15537895
Kunishige M et al. Isolated cranial neuropathy associated with anti-glycolipid antibodies. 2004 J. Neurol. Sci. pmid:15465085
Aoki H et al. Inhibition of motility and invasiveness of renal cell carcinoma induced by short interfering RNA transfection of beta 1,4GalNAc transferase. 2004 FEBS Lett. pmid:15178323
Andersen SM et al. Synthesis of ganglioside epitopes for oligosaccharide specific immunoadsorption therapy of Guillian-Barré syndrome. 2004 Org. Biomol. Chem. pmid:15064799
Higashi H and Chen NH Ganglioside/protein kinase signals triggering cytoskeletal actin reorganization. 2004 Glycoconj. J. pmid:14973370
Yamato O et al. Laboratory diagnosis of canine GM2-gangliosidosis using blood and cerebrospinal fluid. 2004 J. Vet. Diagn. Invest. pmid:14974845